CLEVIPREX

This brand name is authorized in United States. It is also authorized in Austria, France, Netherlands, New Zealand, Spain.

Active ingredients

The drug CLEVIPREX contains one active pharmaceutical ingredient (API):

1	Clevidipine UNII 19O2GP3B7Q - CLEVIDIPINE
	Clevidipine is a dihydropyridine L-type calcium channel blocker. L-type calcium channels mediate the influx of calcium during depolarization in arterialsmooth muscle. Experiments in anesthetized rats and dogs show that clevidipine reduces mean arterial blood pressure by decreasing systemic vascular resistance.
	Read more about Clevidipine

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
CLEVIPREX Emulsion for infusion	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
C08CA16		C Cardiovascular system → C08 Calcium channel blockers → C08C Selective calcium channel blockers with mainly vascular effects → C08CA Dihydropyridine derivatives
Discover more medicines within C08CA16

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
ES	Centro de información online de medicamentos de la AEMPS	76595
FR	Base de données publique des médicaments	64628249
NL	Z-Index G-Standaard, PRK	131032
NZ	Medicines and Medical Devices Safety Authority	13768
US	FDA, National Drug Code	10122-610, 10122-611, 18124-011